Recap: Galmed Pharmaceuticals Q1 Earnings
Portfolio Pulse from Benzinga Insights
Galmed Pharmaceuticals (NASDAQ:GLMD) reported Q1 earnings, beating estimated earnings by 27.33% with an EPS of $-1.09 compared to an estimate of $-1.5. Revenue remained unchanged from the same period last year. Last quarter, the company beat EPS by $0.6, resulting in a 4.42% share price increase the next day.
June 01, 2023 | 1:40 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Galmed Pharmaceuticals beat Q1 earnings estimates by 27.33% with an EPS of $-1.09. Last quarter, a similar EPS beat resulted in a 4.42% share price increase the next day.
Galmed Pharmaceuticals beat Q1 earnings estimates, which is a positive signal for investors. The company's past performance shows that a similar EPS beat last quarter led to a 4.42% share price increase the next day. This suggests that the stock price is likely to go up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100